Shun Yao 2.0 Focuses on LT3001
Shuntian Pharma (6535) on 13日 unveiled its "Shun Yao 2.0" strategy at an investor briefing, streamlining assets and focusing resources to advance pivotal clinical trials centered on stroke drug LT3001, while building two cutting-edge platforms in in-vivo CAR-T and next-generation gene editing. The company will shift to a diversified value-creation model combining clinical development, technology licensing and international collaboration, launching three new growth engines.
206 Trial First Case Meets Expectations
For the highly watched mechanism validation of LT3001, the 206 exploratory imaging trial targeting 10人 has successfully completed enrollment of its first subject. Preliminary imaging results met the team's expectations, providing the first real World data for LT3001's innovative thrombolytic mechanism. The company is now accelerating subsequent enrollment and, to ensure rigor, plans to disclose details externally after accumulating more clinical data.
207 Bridging Trial Begins Enrollment
The China Phase II/III seamless bridging 207 trial in collaboration with Shanghai Pharma has begun enrollment, focusing on disabled stroke patients within 24小時內 who have not received intravenous thrombolysis or thrombectomy, with Phase II expected to enroll 300人. Among 30家 target sites, 28家 have passed ethics review and 19家 have been activated, with a cumulative 2人 enrolled. In addition, for the treatment strategy combining LT3001 after thrombectomy, Trial 203 Part A has been completed with good safety, with the next step planned in 2027 to conduct a multi-dose controlled trial to expand the eligible population.
p40 Armor and Gene-Editing Engine
The second new growth engine is cell therapy, with Shun Yao introducing p40 armor technology, using p19 naturally present in tumor-antigen-activated T cells supplemented with p40 to form IL-23 signaling, a safety-lock model that selectively enhances T cells and improves safety. Animal studies show that for different cancer types, the p40 armor can effectively overcome technical bottlenecks, with 平Taihua potential. Shun Yao adopts an IP per-target licensing, asset-light strategy without building its own cell manufacturing or fully undertaking clinical development, initially licensing a small number of targets to different CAR-T developers, with multiple CAR-T developers already in active discussions.
Teaming Up with YinZhengji Gene to Target Rare Diseases
The third new growth engine is gene editing. Leveraging the technological strengths of YinZhengji Gene, the company is actively deploying next-generation CRISPR gene editing. CRISPR technology has evolved from single-point gene knockout and replacement to enabling large-fragment gene substitution. Shun Yao will launch in-depth collaboration with YinZhengji Gene, combining its long-accumulated development expertise in the central nervous system field with new-generation gene-editing technology to explore therapeutic potential in rare diseases. The two parties plan to complete disease and target screening this year and advance animal proof-of-concept next year, using early efficacy and delivery feasibility data to increase asset maturity and pursue international licensing or co-development.